Browse > Article
http://dx.doi.org/10.3345/kjp.2007.50.12.1217

The effects of shortened dexamethasone administration on remission rate and potential complications during remission induction treatment for pediatric acute lymphoblastic leukemia  

Lee, Jae Wook (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Lee, Kwang Hee (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Kwon, Young Joo (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Lee, Dae Hyoung (Department of Pediatrics, College of Medicine, Hallym University)
Chung, Nak Gyun (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Jeong, Dae Chul (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Cho, Bin (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Kim, Hack Ki (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
Publication Information
Clinical and Experimental Pediatrics / v.50, no.12, 2007 , pp. 1217-1224 More about this Journal
Abstract
Purpose : Due to its high potency against leukemic blasts, our institution has opted for the use of dexamethasone during acute lymphoblastic leukemia (ALL) remission induction, but in our most recent treatment protocol, CMCPL-2005, we shortened the length of steroid treatment from 4 to 3 weeks. We compared both the rates of remission induction and significant complications observed during induction with CMCPL-2005, with those noted for our previous protocol, CMCPL-2001. Methods : We retrospectively reviewed the records of patients diagnosed with ALL from January, 2001 to December, 2006 at the Department of Pediatrics, St. Mary's Hospital, the Catholic University of Korea. Data concerning age, sex, WBC count at diagnosis, immunophenotype, cytogenetic traits, and risk group were collected for each patient. Results of remission induction treatment were compared between the two patient groups. Infection and other major complications resulting from treatment were investigated according to NCI toxicity criteria. Results : A total of 141 and 88 patients received remission induction under CMCPL-2001 and CMCPL-2005 respectively. In the CMCPL-2001 group, 136 (96%) achieved complete remission while 82 (93%) achieved CR in the CMCPL-2005 group. Patients in the CMCPL-2005 group were more likely to undergo remission induction without experiencing major complications. However, with regards to steroid related toxicities such as infection, no significant differences were noted. Conclusion : We shortened the length of steroid administration from four to three weeks, yet found the remission induction rate to be comparable to that of our previous regimen. However, rates of steroid related toxicities such as infectious complications remain unchanged despite shortened exposure to dexamethasone.
Keywords
Acute Lymphoblastic Leukemia; Remission induction; Dexamethasone;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998;339:605-15   DOI   ScienceOn
2 Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-78   DOI   ScienceOn
3 Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M. Infectious toxicity of dexamethasone during ALL remission-induction chemotherapy: report of two cases and literature review. Pediatr Hematol Oncol 2004;21:27-35   DOI   ScienceOn
4 Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003;101: 3809-17   DOI   ScienceOn
5 Gaynon PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 1997;80:1717-26   DOI   ScienceOn
6 Hann I, Vora A, Harrison G, Harrison C, Eden O, Hill F, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol 2001;113:103-14   DOI   ScienceOn
7 Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000;14:2223-33
8 Hurwitz CA, Silverman LB, Schorin MA, Clavell LA, Dalton VK, Glick KM, et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 2000;88:1964-9   DOI   ScienceOn
9 Belgaumi AF, Al-Bakrah M, Al-Mahr M, Al-Jefri A, Al- Musa A, Saleh M, et al. Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer 2003;97:2898-903   DOI   ScienceOn
10 Mattano LA Jr, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol 2000;18:3262-72   DOI
11 Jones B, Freeman AI, Shuster JJ, Jacquillat C, Weil M, Pochedly C, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 1991;19:269-75   DOI   ScienceOn
12 Yetgin S, Tuncer MA, Cetin M, Gumruk F, Yenicesu I, Tunc B, et al. Benefit of high-dose methlyprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up. Leukemia 2003;17:328-33   DOI   ScienceOn
13 Igarashi S, Manabe A, Ohara A, Kumagai M, Saito T, Okimoto Y, et al. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediaterisk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 Protocol. J Clin Oncol 2005;23:6489-98   DOI   ScienceOn
14 Ito C, Evans WE, McNinch L, Coustan-Smith E, Mahmoud H, Pui CH, et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol 1996;14:2370-6   DOI
15 Chung NG, Lee SJ, Kim SY, Jang PS, Cho B, Jeong DC, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. Korean J Pediatr Hematol-Oncol 2003;10:189-97
16 Waber DP, Carpentieri SC, Klar N, Silverman LB, Schwenn M, Hurwitz CA, et al. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol 2000;22:206-13   DOI   ScienceOn
17 Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood 2000;96:24-33
18 Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-8   DOI   ScienceOn
19 Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-33
20 Schwartz CL, Thompson EB, Gelber RD, Young ML, Chilton D, Cohen HJ, et al. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol 2001;19:1040-6   DOI
21 Estlin EJ, Ronghe M, Burke GA, Yule SM. The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukemia. Br J Haematol 2000;110:780-90   DOI   ScienceOn
22 Pui C-H. Childhood leukemias. N Engl J Med 1995;332: 1618-30   DOI   ScienceOn